X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VB421 binds to IGF-1R with sub-50 pM potency and possesses favorable biophysical properties that may provide a differentiated product profile relative to other anti-IGF-1R antibodies.
Lead Product(s): Lonigutamab
Therapeutic Area: Immunology Product Name: VB421
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. ValenzaBio plans to initiate clinical studies of VB517 in 2023.
Lead Product(s): VB517
Therapeutic Area: Dermatology Product Name: VB517
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Novelty Nobility
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2022
Details:
The fundraise will support the advancement and expansion of ValenzaBio’s pipeline toward clinical development, including VB119, anti-CD19 monoclonal antibody for the treatment of membranous nephropathy and VB421, an anti-IGF-1R antibody.
Lead Product(s): CD19-targeting mAb
Therapeutic Area: Immunology Product Name: VB119
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fidelity Management & Research Company
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
